RxDoctor Payments Data

Susan King, MD

Family Medicine · Cedar Park, TXNPI 1669459327

Payments from drug & device makers

$56,622in general payments, 2019–2025

Across 208 payments — averaging $272.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$26K
  • AstraZeneca$20K
  • Sumitomo Pharma America, Inc.$5K
  • AMAG Pharmaceuticals, Inc.$4K
  • Amgen$846
  • Galderma Laboratories, L.p.$266
  • plus $629 from 14 others

What the payments were for

  • Consulting fees$3,50049%
  • Speaking & faculty fees$1502%
  • Travel & lodging$70510%
  • Food & beverage$2,65737%
  • Education$1142%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,622 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$111,619
Medicare patients
245
Services billed
1,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$81,824
OzempicSemaglutide38$58,627
MounjaroTirzepatide28$36,987
TrulicityDulaglutide19$25,212
EliquisApixaban19$20,130
Synjardy XrEmpagliflozin/Metformin Hcl11$6,459
JanuviaSitagliptin Phosphate11$6,135
Rosuvastatin Calcium354$4,713
Duloxetine Hcl115$2,253
Levothyroxine Sodium192$2,242
SynthroidLevothyroxine Sodium24$1,743
Bupropion XlBupropion Hcl73$1,619
Metoprolol Succinate97$1,563
Olmesartan Medoxomil66$1,480
ValacyclovirValacyclovir Hcl18$1,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$19,779$81,82482 claims
Lilly USA, LLCMounjaro, Trulicity$35$62,19947 claims
Novo NordiskOzempic$166$58,62738 claims
Boehringer IngelheimSynjardy Xr$37$6,45911 claims
AbbVieSynthroid$70$1,74324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cedar Park

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →